Royal Bank of Canada Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00

Jasper Therapeutics (NASDAQ:JSPR) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $48.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

Several other equities research analysts have also recently commented on the stock. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Finally, JMP Securities restated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Buy” and an average target price of $67.75.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $7.05 on Thursday. Jasper Therapeutics has a 1 year low of $6.57 and a 1 year high of $31.01. The firm has a market cap of $105.76 million, a P/E ratio of -1.49 and a beta of 2.18. The stock has a fifty day moving average price of $21.37 and a two-hundred day moving average price of $20.27.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JSPR. BNP Paribas Financial Markets boosted its position in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $59,000. MetLife Investment Management LLC grew its position in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares in the last quarter. Jane Street Group LLC purchased a new position in Jasper Therapeutics during the third quarter valued at approximately $251,000. Finally, Rhumbline Advisers acquired a new position in Jasper Therapeutics in the 2nd quarter valued at approximately $300,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.